Omega-3 Fatty Acids for Neuroprotection in Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions involving damage to the nervous system, such as peripheral neuropathy and glaucoma, are inadequate in providing effective neuroprotection and often have significant side effects, with a need for alternative therapies that can improve visual acuity and reduce progression of these diseases.
Innovation Solution
Administration of high doses of omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in specific ratios, either alone or combined with other therapeutic agents, to provide neuroprotection and improve visual outcomes in patients with nerve damage due to glaucoma, inflammation, or trauma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for nervous system damage (such as steroids and immunosuppressive agents) are used, then inflammation can be suppressed, but significant side effects occur and neuroprotection is inadequate
Solution Approach 1:
The patent changes the chemical composition parameter by using omega-3 fatty acids (EPA and DHA) instead of traditional steroids and immunosuppressive agents. This substitution maintains anti-inflammatory and neuroprotective effects while significantly reducing harmful side effects associated with conventional treatments.
Solution Approach 2:
The patent employs natural omega-3 fatty acids derived from fish oil as a safer, more accessible alternative to expensive and harmful pharmaceutical interventions. These natural compounds provide effective neuroprotection without the severe side effects of long-term steroid use.
2Stress or pressure
If intraocular pressure-based therapies are used for glaucoma, then intraocular pressure can be controlled, but visual acuity improvement and disease progression reduction are limited
Solution Approach 1:
The patent combines intraocular pressure control with neuroprotective effects by administering omega-3 fatty acids alongside conventional glaucoma therapies. This dual-action approach simultaneously manages pressure while providing direct neuroprotection to retinal ganglion cells, thereby improving visual acuity outcomes beyond what pressure control alone achieves.
Solution Approach 2:
Omega-3 fatty acids act as an intermediary substance that mediates between intraocular pressure control and neuronal protection. They provide a protective buffer for nerve cells against pressure-related damage and other insults, bridging the gap between pressure management and visual function preservation.
3Reliability
If high doses of omega-3 fatty acids are administered, then neuroprotection and visual acuity improvement are significantly enhanced, but treatment complexity and dosage management become more challenging
Solution Approach 1:
The patent recommends preliminary assessment of patients' dietary omega-3 intake and existing supplementation before initiating high-dose therapy. This preliminary evaluation allows for personalized dosage determination that maximizes neuroprotective benefits while minimizing treatment complexity and potential adverse effects.
Data Source
AI summary
Method of administering compositions comprising omega 3 fatty acids for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system.